- Home
- OLO vs PHVS Comparison
OLO vs PHVS Comparison
Compare OLO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- PHVS
- Stock Information
- Founded
- OLO 2005
- PHVS 2015
- Country
- OLO United States
- PHVS Netherlands
- Employees
- OLO N/A
- PHVS N/A
- Industry
- OLO Major Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- PHVS Health Care
- Exchange
- OLO Nasdaq
- PHVS Nasdaq
- Market Cap
- OLO 1.3B
- PHVS 1.0B
- IPO Year
- OLO 2021
- PHVS 2021
- Fundamental
- Price
- OLO $7.85
- PHVS $19.14
- Analyst Decision
- OLO Buy
- PHVS Strong Buy
- Analyst Count
- OLO 3
- PHVS 5
- Target Price
- OLO $8.67
- PHVS $40.60
- AVG Volume (30 Days)
- OLO 1.2M
- PHVS 46.7K
- Earning Date
- OLO 02-19-2025
- PHVS 11-13-2024
- Dividend Yield
- OLO N/A
- PHVS N/A
- EPS Growth
- OLO N/A
- PHVS N/A
- EPS
- OLO N/A
- PHVS N/A
- Revenue
- OLO $271,872,000.00
- PHVS N/A
- Revenue This Year
- OLO $24.59
- PHVS N/A
- Revenue Next Year
- OLO $15.65
- PHVS N/A
- P/E Ratio
- OLO N/A
- PHVS N/A
- Revenue Growth
- OLO 26.41
- PHVS N/A
- 52 Week Low
- OLO $4.20
- PHVS $15.21
- 52 Week High
- OLO $8.35
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- OLO 57.75
- PHVS 55.68
- Support Level
- OLO $7.46
- PHVS $15.21
- Resistance Level
- OLO $7.75
- PHVS $19.59
- Average True Range (ATR)
- OLO 0.29
- PHVS 1.42
- MACD
- OLO -0.04
- PHVS 0.14
- Stochastic Oscillator
- OLO 62.31
- PHVS 93.82
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.